Barry Duplantis - Immunoprecise Antibodies VP Relations
| IPA Stock | USD 0.38 0.03 8.57% |
Insider
Barry Duplantis is VP Relations of Immunoprecise Antibodies
| Address | 3204?4464 Markham Street, Victoria, BC, Canada, V8Z 7X8 |
| Phone | 250 483 0308 |
| Web | https://www.ipatherapeutics.com |
Immunoprecise Antibodies Management Efficiency
The company has Return on Asset of (0.1345) % which means that on every $100 spent on assets, it lost $0.1345. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.6404) %, meaning that it generated no profit with money invested by stockholders. Immunoprecise Antibodies' management efficiency ratios could be used to measure how well Immunoprecise Antibodies manages its routine affairs as well as how well it operates its assets and liabilities. At present, Immunoprecise Antibodies' Return On Capital Employed is projected to slightly decrease based on the last few years of reporting. The current year's Return On Equity is expected to grow to 0.30, whereas Return On Tangible Assets are forecasted to decline to (1.39). At present, Immunoprecise Antibodies' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 50.9 M, whereas Total Current Assets are forecasted to decline to about 6 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Kimberly Sheehan | Milestone Pharmaceuticals | N/A | |
| FACC MD | Milestone Pharmaceuticals | 60 | |
| BBA CPA | Lumos Pharma | 57 | |
| James Ahlers | RenovoRx | 60 | |
| Jo PalmerPhillips | Eliem Therapeutics | N/A | |
| MD BA | Lumos Pharma | 69 | |
| Katherine Taudvin | Scpharmaceuticals | N/A | |
| Dr Dubensky | Tempest Therapeutics | 66 | |
| James JD | Eliem Therapeutics | 58 | |
| Jeff Nelson | Milestone Pharmaceuticals | 43 | |
| Angela Nelms | RenovoRx | 47 | |
| Peter Rhode | HCW Biologics | 66 | |
| Ramtin MD | RenovoRx | 58 | |
| Anne Moon | Tempest Therapeutics | N/A | |
| Lisa Miller | Lumos Pharma | N/A | |
| Guy Rousseau | Milestone Pharmaceuticals | N/A | |
| Erin Lavelle | Eliem Therapeutics | 47 | |
| Lori CPA | Lumos Pharma | 40 | |
| MBA MD | Eliem Therapeutics | 63 | |
| RAC Sakai | Tempest Therapeutics | N/A | |
| Carl Langren | Lumos Pharma | 69 | |
Management Performance
| Return On Equity | -0.64 | ||||
| Return On Asset | -0.13 |
Immunoprecise Antibodies Leadership Team
Elected by the shareholders, the Immunoprecise Antibodies' board of directors comprises two types of representatives: Immunoprecise Antibodies inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Immunoprecise. The board's role is to monitor Immunoprecise Antibodies' management team and ensure that shareholders' interests are well served. Immunoprecise Antibodies' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Immunoprecise Antibodies' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kari Graber, Vice Services | ||
| Brad McConn, Chief Officer | ||
| Barry Duplantis, VP Relations | ||
| Ilse Roodink, Chief Officer | ||
| David Orton, Chief Officer | ||
| Roland Romijn, Head IPA | ||
| Jennifer Bath, President CEO | ||
| Carla Dahl, VP Marketing |
Immunoprecise Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Immunoprecise Antibodies a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.64 | ||||
| Return On Asset | -0.13 | ||||
| Profit Margin | (1.15) % | ||||
| Operating Margin | (0.86) % | ||||
| Current Valuation | 19.56 M | ||||
| Shares Outstanding | 28.83 M | ||||
| Shares Owned By Insiders | 12.05 % | ||||
| Shares Owned By Institutions | 6.50 % | ||||
| Number Of Shares Shorted | 666.14 K | ||||
| Price To Book | 0.46 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Immunoprecise Antibodies offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Immunoprecise Antibodies' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Immunoprecise Antibodies Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Immunoprecise Antibodies Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunoprecise Antibodies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For information on how to trade Immunoprecise Stock refer to our How to Trade Immunoprecise Stock guide.You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunoprecise Antibodies. If investors know Immunoprecise will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunoprecise Antibodies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.77) | Revenue Per Share 0.921 | Quarterly Revenue Growth (0.07) | Return On Assets (0.13) | Return On Equity (0.64) |
The market value of Immunoprecise Antibodies is measured differently than its book value, which is the value of Immunoprecise that is recorded on the company's balance sheet. Investors also form their own opinion of Immunoprecise Antibodies' value that differs from its market value or its book value, called intrinsic value, which is Immunoprecise Antibodies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunoprecise Antibodies' market value can be influenced by many factors that don't directly affect Immunoprecise Antibodies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunoprecise Antibodies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunoprecise Antibodies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunoprecise Antibodies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.